Abstract
We have recently isolated the erythroleukemic cell line, HB60-5, that proliferates in the presence of erythropoietin (Epo) and stem cell factor (SCF), but undergoes terminal differentiation in the presence of Epo alone. Ectopic expression of the ets related transcription factor Fli-1 in these cells resulted in the establishment of the Epo-dependent cell line HB60-ED that proliferates in the presence of Epo. In this study, we utilized these two cell lines to examine the signal transduction pathways that are activated in response to Epo and SCF stimulation. We demonstrate that Epo, but not SCF, phosphorylates STAT-5 in both HB60-5 and HB60-ED cells. Interestingly, SCF activates the Shc/ras pathway in HB60-5 cells while Epo does not. However, both Epo and SCF are capable of activating the Shc/ras pathway in HB60-ED cells. Furthermore, enforced expression of gp55 in HB60-5 cells by means of infection with the Spleen Focus Forming virus-P (SFFV-P), confers Epo independent growth, which is associated with the up-regulation of Fli-1. Activation of the Shc/ras pathway is readily detected in gp55 expressing cells in response to both Epo and SCF, and is associated with a block in STAT-5B tyrosine phosphorylation. These results suggest that STAT-5 activation, in the absence of Shc/ras activation, plays a role in erythroid differentiation. Moreover, Fli-1 is capable of switching Epo-induced differentiation to Epo-induced proliferation, suggesting that this ets factor regulated genes whose products modulate the Epo-Epo-R signal transduction pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ben-David Y and Bernstein A . 1991 Cell 66: 831–834
Ben-David Y, Giddens EB and Bernstein A . 1990 Proc Natl Acad Sci USA 87: 1332–1336
Ben-David Y, Giddens EG, Letwin K and Bernstein A . 1991 Genes Devel 5: 908–918
Ben-David Y, Prideaux VR, Chow V, Benchimol S and Bernstein A . 1988 Oncogene 3: 179–185
Brizzi MF, Dentelli P Rosso A, Yarden Y and Pegoraro L . 1999 J Biol Chem 274: 16965–16972
Damen JE, Cutler RL, Jiao H, Yi T and Krystal G . 1995a J Biol Chem 270: 23402–23408
Damen JE, Liu L, Cutler RL and Krystal G . 1993 Blood 82: 2296–2303
Damen JE, Liu L, Rosten P, Humphries RK, Jefferson, AB, Majerus PW and Krystal G . 1996 Proc Natl Acad Sci USA 93: 1689–1693
Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL and Krystal G . 1995b EMBO J 14: 5557–5568
Fowles LF, Martin ML, Nelsen L, Stacey KJ, Redd D, Clark YM, Nagamine Y, McMahon M, Hume DA and Ostrowski MC . 1998 Mol Cell Biol 18: 5148–5156
Gouilleux F, Pallard C, Dusanter-Fourt I, Wakao H, Haldosen LA, Norstedt G, Levy D and Groner B 1995 . EMBO J, 14 2005–2013
Gregory RC, Jiang N, Todokoro K, Crouse J, Pacific RE and Wojchowski DM . 1998 Blood 92: 1104–1118
Hankins Wd, Chin DL, Dons R and Sigounas G . 1989 Ann NY Acad Sci 554: 21–28
He TC, Jiang N, Zhuang H and Wojchowski DM . 1995 J Biol Chem 270: 11055–11061
Hicks GG and Mowat M . 1988 J Virol 62: 4752–4755
Howard JC, Berger L, Bani MR, Hawley R and Ben-David Y . 1996 Oncogene 12: 1405–1415
Howard JC, Yousefi S, Cheong G, Bernstein A and Ben-David Y . 1993 Oncogene 8: 2721–2729
Iwatsuki K, Endo T, Misawa H, Yokouchi M, Matsumoto A, Ohtsubo M, Mori KJ and Yoshimura A . 1997 J Biol Chem 272: 8149–8152
Jacobs-Helber SM, Penta K, Sun Z, Lawson A and Sawyer ST . 1997 J Biol Chem 272: 6850–6853
Janknecht R . 1996 Mol Cell Biol 16: 1550–1556
Johnson P, Chung S and Benchimol S . 1993 Mol Cell Biol 13: 1456–1463
Kabat D . 1990 Curr Top Microbiol Immunol 148: 1–42
Kinashi T, Escobedo JA, Williams LT, Takatsu K and Springer TA . 1995 Blood 82: 2086–2090
Koury MJ and Bondurant MC . 1990 Science 248: 378–381
Lecoq-Lafon C, Verdier F, Fichelson S, Chretien S, Gisselbrecht S, Lacombe C and Mayeux P . 1999 Blood 93: 2578–2585
Lev S, Givol D and Yarden Y . 1992 Proc Natl Acad Sci USA 89: 678–682
Li JP, D'Andrea AD, Lodish HF and Baltimore D . 1990 Nature 343: 762–764
Liboi E, Carroll M, D'Andrea AD and Mathey-Prevot B . 1993 Proc Natl Acad Sci USA 90: 11351–11355
Markowitz D, Goff S and Bank A . 1988 J Virol 62: 1120
McDonald J, Beru N and Goldwasser E . 1987 Mol Cell Biol 7: 365–370
Miura Y, Miura O, Ihle JN and Aoki N . 1994 J Biol Chem 269: 29962–29969
Moreau-Gachelin F, Tavitian A and Tambourin P . 1988 Nature 331: 277–280
Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC and Ihle JN . 1999 Immunity 10: 249–259
Mui AL, Wakao H, O'Farrell AM, Harada N and Miyajima A . 1995 EMBO J 14: 1166–1175
O'Hagan RC, Tozer RG, Symons M, McCormick F and Hassell JA . 1996 Oncogene 13: 1323–1333
Pallard C, Gouilleux F, Benit L, Cocault L, Souyri M, Levy D, Groner B, Gisselbrecht S and Dusanter-Fourt I . 1995 EMBO J 14: 2847–2856
Pawson T and Bernstein A . 1990 Trends Genet 6: 350–356
Penta K and Sawyer ST . 1995 J Biol Chem 270: 31282–31287
Pereira R, Quang CT, Lesault I, Dolznig H, Beug H and Ghysdael J . 1999 Oncogene 18: 1597–1608
Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV and Griffin JD . 1997 J Biol Chem 272: 10248–10253
Socolovsky M, Fallon AE, Wang S, Brugnara C and Lodish HF . 1999 Cell 93: 181–191
Sui X, Krantz SB, You M and Zhao Z . 1998 Blood 92: 1142–1149
Tamir A, Howard J, Higgins RR, Li YJ, Berger L, Zacksenhaus E, Reis M and Ben-David Y . 1999 Mol Cell Biol 19: 4452–4464
Tauchi T, Boswell HS, Leibowitz D and Broxmeyer HE . 1994 J Exp Med 179: 167–175
Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G and Ihle JN . 1998 Cell 93: 841–850
Timokhina I, Kissel H, Stella G and Besmer P . 1998 EMBO J 17: 6250–6262
Verdier F, Chretien S, Billar C, Gisselbrecht S, Lacombe C and Mayeux P . 1997 J Biol Chem 272: 26173–26178
Wakao H, Harada N, Kitamura T, Mui AL and Miyajima A . 1995 EMBO J 14: 2527–2535
Wasylyk B, Hagman J and Gutierrez-Hartmann A . 1998 Trends Biochem Sci 23: 213–216
Wu H, Klingmuller U, Besmer P and Lodish HF . 1995 Nature 377: 242–243
Yamamura Y, Senda H, Kageyama Y, Matsuzaki T, Noda M and Ikawa Y . 1998 Mol Cell Biol 18: 1172–1180
Youssoufian H, Longmore G, Neumann D, Yoshimura A and Lodish HF . 1993 Blood 81: 2223–2236
Acknowledgements
We thank Dr Jane McGlade for the generous gift of Shc antibody. We also thank Drs Kirill Rosen for his comment on the manuscript and Lynda Woodcock for help in preparation of the manuscript. This work was supported by grants from the National Cancer Institute of Canada to Y Ben-David and SA Berger and Medical Research Council of Canada to D Dumont. RR Higgins was supported by a fellowship from the Leukemia Research Fund of Canada.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zochodne, B., Truong, A., Stetler, K. et al. Epo regulates erythroid proliferation and differentiation through distinct signaling pathways: implication for erythropoiesis and Friend virus-induced erythroleukemia. Oncogene 19, 2296–2304 (2000). https://doi.org/10.1038/sj.onc.1203590
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203590
Keywords
This article is cited by
-
Current insights into the role of Fli-1 in hematopoiesis and malignant transformation
Cellular and Molecular Life Sciences (2022)
-
The ets transcription factor Fli-1 in development, cancer and disease
Oncogene (2015)
-
Drug-mediated inhibition of Fli-1 for the treatment of leukemia
Blood Cancer Journal (2012)
-
Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia
Leukemia (2009)
-
Direct transcriptional regulation of MDM2 by Fli-1
Oncogene (2005)